Custom Search


Sunday 01 December 2002

SLE - Rituximab in lupus.

By: Eisenberg R.

Arthritis Res Ther 2003;5(4):157-9

B cells are essential to the development of systemic lupus erythematosus (SLE). The chimeric monoclonal antibody rituximab depletes B cells by targeting the pan-B-cell surface marker CD20. Preliminary experience with this agent in SLE and other autoimmune diseases has been encouraging. Controlled trials in SLE will be necessary to determine whether rituximab is useful therapy in this disease, and will teach us more about the roles of B cells in its pathogenesis.

Use of this site is subject to the following terms of use